PER Percheron Therapeutics Limited
Healthcare · Drug Manufacturers - Specialty & Generic
· website
$0.00
52wk 0.00 – 0.01
Overall
35.2
Value
84.0
Growth
0.0
Health
69.2
Quality
0.0
Momentum
6.9
Dividend
—
Price
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | -20.0% |
| 3 months | 14.3% |
| 6 months | -20.0% |
| 1 year | -63.6% |
| 3 years | -94.2% |
Risk
| Volatility (1y ann.) | 173.7% |
| Beta vs ASX 200 | -0.06 |
| Sharpe (1y) | 0.25 |
| VaR 95% (1-day) | -20.0% |
| Max drawdown (1y) | -80.0% |
| Off 1-year high | -60.0% |
Technicals
| RSI(14) | 45 |
| vs 50DMA | -7.8% |
| vs 200DMA | -24.9% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
84.0
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
15
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
6.9
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
11
Position in 52-week range
22
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$7.29M
P/E (trailing)
—
P/E (forward)
-0.85
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
1.10
EV / EBITDA
-0.45
Price / Book
0.80
ROE
-54.7%
Operating margin
-222.6%
Net margin
0.0%
Total cash
$4.05M
Total debt
$27,786
Current ratio
7.64
Debt / Equity
0.00
Free cash flow
$-6.25M
Avg volume
3.31M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$5.62M
- Net income-$4.79M
- Diluted EPS—
- Free cash flow-$8.05M
- Net debt-$4.02M